TEVA-SALBUTAMOL HFA METERED-DOSE AEROSOL

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

SALBUTAMOL (SALBUTAMOL SULFATE)

から入手可能:

TEVA CANADA LIMITED

ATCコード:

R03AC02

INN（国際名）:

SALBUTAMOL

投薬量:

100MCG

医薬品形態:

METERED-DOSE AEROSOL

構図:

SALBUTAMOL (SALBUTAMOL SULFATE) 100MCG

投与経路:

INHALATION

パッケージ内のユニット:

200 DOSES

処方タイプ:

Prescription

治療領域:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

製品概要:

Active ingredient group (AIG) number: 0108887013; AHFS:

認証ステータス:

APPROVED

承認日:

2009-12-07

製品の特徴

_Page 1_
PRODUCT MONOGRAPH
Pr
TEVA-SALBUTAMOL HFA
salbutamol (as salbutamol sulfate)
Inhalation Aerosol
100 mcg salbutamol per actuation
Bronchodilator
(beta
2
-adrenergic agonist)
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
www.tevacanada.com
Submission Control No: 213098
Date of Revision:
March 20, 2018
_Page 2_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
....................................................................................................
3
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
....................................................................................................
7
DRUG INTERACTIONS
..................................................................................................
10
DOSAGE AND ADMINISTRATION
..............................................................................
11
OVERDOSAGE
.................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 13
STORAGE AND STABILITY
..........................................................................................
15
SPECIAL HANDLING INSTRUCTIONS
........................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 15
PART II: SCIENTIFIC INFORMATION
...............................................................................
16
PHARMACEUTICAL INFORMATION
..........................................................................
16
CLINICAL TRIALS
..........................